Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Paul Dent,
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, there was an error in the Conflict of Interest statement. We neglected to include that the author Paul Dent, is a paid consultant and a Key Advisor for Genzada Pharmaceuticals. The correct statement appears below.
“PD has received funding support from Genzada Pharmaceuticals Inc. for these studies. CW is a paid officer of the company. DH is a paid consultant and a Key Scientific advisor to the company. PD is a paid consultant and a Key Advisor for Genzada Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.